Protein Glycosylation Influences Soluble Urokinase Plasminogen Activator Receptor (suPAR) Measurements

Elevated plasma levels of the biomarker soluble urokinase plasminogen activator receptor (suPAR) are prognostic of adverse outcomes in cardiovascular disease (CVD). This novel inflammatory protein has five known N-linked glycosylation sites, but the contribution of glycosylation to disease progression is unknown. This study aimed to assess the impact of glycosylation on suPAR measurements.